U.S. Logistics Stock News

If you are wondering whether Semtech at around $72.89 is still worth a closer look, or if the big money has already been made, you are in the right place to work out what the current price really implies. The stock has pulled back about 8.4% over the last week, but it is still up 7.8% over 30 days and 17.4% year to date, with a 163.1% gain over 3 years that naturally raises questions about what comes next. Recent moves have been driven by growing investor attention on Semtech's role in...

Earlier this week, Guardant Health and Trial Library announced a collaboration to pair Guardant’s precision oncology diagnostics and real-world genomic data with Trial Library’s AI-powered matching and navigation platform, aiming to improve identification, referral and enrollment of cancer patients into clinical trials across more than 320 clinics and 1,500 providers in the United States. This partnership is distinctive because it connects Guardant’s data from over 1 million tested patients...

Recently released analysis highlighted that Constellation Brands’ rankings for financial strength, growth, valuation and predictability have weakened, with elevated debt levels and uncertain growth now weighing on perceptions of the business. An interesting implication is that the company’s historically important reputation for consistency is under renewed scrutiny, as lower predictability scores raise fresh questions about the reliability of its future revenue and earnings trends. Next,...

Wondering if Affirm Holdings is still worth your attention after its massive run a few years back, or if the story has quietly changed while no one was looking? After a huge 3 year gain of 564.5%, the stock has cooled off recently, slipping 1.1% over the last week, 14.8% over the last month, and sitting at a modest 7.6% gain year to date with a 4.9% loss over the past year. Recent moves have come as investors reassess buy now, pay later players like Affirm in light of shifting consumer...

If you are wondering whether Tilray Brands is finally a smart buy or just another volatile cannabis story, you are not alone. That is exactly what we are going to unpack here. The stock has surged about 65.3% over the past week, even though it is still down year to date and has had a rough 3 year stretch. This shows that sentiment can flip quickly when this name gets attention. Recently, Tilray has been in the spotlight as investors react to shifting expectations around US cannabis policy...

In late September 2025, MoonLake Immunotherapeutics revealed that its only drug candidate, sonelokimab, delivered disappointing Phase 3 results, leading to multiple securities class action lawsuits alleging the company misled investors about the drug’s efficacy and Nanobody advantages. The litigation centers on claims that MoonLake overstated sonelokimab’s superiority versus an existing treatment while allegedly not fully disclosing their similar biological targets and unproven clinical...

Celcuity (CELC) recently presented new Phase 3 VIKTORIA-1 data for gedatolisib to oncologists at the San Antonio Breast Cancer Symposium, showing clearly longer progression free survival versus fulvestrant in advanced HR positive, HER2 negative disease. See our latest analysis for Celcuity. These latest VIKTORIA-1 results land after a remarkable run for Celcuity, with a 30 day share price return of 23.61 percent and a 1 year total shareholder return of 740.65 percent, which some investors may...

The Brink's Company recently announced that its board approved a new share repurchase program authorizing up to US$750 million in buybacks, with the plan set to run through December 31, 2027. This authorization amounts to more than 15% of Brink's current market value, signaling management’s confidence in its cash generation and AMS/DRS-led growth strategy. Next, we’ll examine how Brink’s sizable new buyback authorization could reshape the existing investment narrative around capital...

Regencell Bioscience Holdings (NasdaqCM:RGC) has been under pressure after disclosing a Department of Justice subpoena into trading activity and its operational, financial, and accounting practices, a development that immediately sharpened investors focus on legal and governance risks. See our latest analysis for Regencell Bioscience Holdings. Even with the DOJ overhang, Regencell’s share price return has been explosive this year. A year to date surge and a strong 30 day share price gain...

Entegris (ENTG) is back in focus after recent investor commentary highlighted a puzzling mix of earnings beats, weaker guidance, and ongoing margin pressure tied to its expansion push in a still soft semiconductor demand environment. See our latest analysis for Entegris. The mixed reaction to Entegris’ latest quarter mirrors its share price story, with a recent 1 month share price return of 10.13 percent, a softer year to date share price return of 4.81 percent, and a 1 year total shareholder...

Recent Performance Sets the Stage Avista (AVA) has slipped about 7% over the past month but is still up around 6% year to date. This combination naturally raises the question of whether the pullback is offering a reasonable entry point. See our latest analysis for Avista. At a share price of $38.56, Avista’s recent 30 day share price return of negative 7.4 percent sits against a more constructive year to date gain and double digit one year total shareholder return. This suggests momentum has...

United Community Banks (UCB) just doubled down on shareholder returns, with its board signing off on a fresh $100 million stock repurchase program running from January 2026 through the end of that year. See our latest analysis for United Community Banks. That new buyback plan lands after a steady climb in sentiment, with a 7.5% 1 month share price return and a 5 year total shareholder return of 33.32%, suggesting momentum is gradually rebuilding from a muted recent patch. If this kind of...

In December 2025, Vestis Corporation reported fourth-quarter sales of US$712.01 million and a quarterly net loss of US$12.55 million, alongside a full-year net loss of US$40.22 million on sales of US$2,734.84 million, reversing the prior year’s profitability. Alongside these widened losses, Vestis guided for fiscal 2026 revenue to be flat to down 2% versus normalized 2025 levels, underscoring management’s cautious outlook on demand and execution. We’ll now examine how Vestis’s wider losses...

Wondering if Kroger at around $63 a share is still a smart buy or if the easy money has already been made? This breakdown is designed to give you a clear, valuation first answer. The stock is up 0.8% over the last week and 2.0% year to date, but that sits against a modest 3.9% gain over 1 year and much stronger returns of 52.4% over 3 years and 127.7% over 5 years, hinting at a long term uptrend that has cooled recently. Recent headlines have centered on Kroger's ongoing antitrust scrutiny...

RPC (RES) has been grinding through a mixed performance lately, with shares slipping over the past week but climbing about 27% in the past 3 months. This has left investors weighing value against cyclical risk. See our latest analysis for RPC. At around $5.68, RPC’s recent 90 day share price return of 27.07% contrasts with a weaker year to date performance. This suggests short term momentum is rebuilding even as longer term total shareholder returns remain uneven. If RPC’s rebound has you...

Wondering if Novo Nordisk is a bargain or a bubble at today’s price? You are not alone, and this breakdown will clarify what you are really paying for. After a volatile stretch, the stock is up 4.8% over the last week but roughly flat over 30 days, while still sitting deep in the red year to date at -42.7% and down -52.1% over the past year, despite a 44.5% gain over five years. Those sharp swings have come as investors reassess the long term outlook for its blockbuster diabetes and obesity...

If you have been wondering whether Under Armour is a bargain or a value trap at these levels, you are not alone. This piece is going to walk through what the current price really implies. Despite the brand’s global recognition, the stock has been sliding, with shares down 4.8% over the last week, 10.0% over the last month, and a much steeper 46.5% year to date, adding up to a 50.9% drop over the past year. That kind of long slide, including a 57.3% loss over three years and 75.1% over five,...

If you have ever looked at ZIM Integrated Shipping Services and wondered whether the current share price really reflects its long term potential, you are not alone. This article is going to unpack that value question clearly. Despite being down 19.5% year to date and slipping 6.3% in the last week, the stock is still up 19.5% over the past month, 22.3% over 1 year and 142.4% over 3 years. This hints at shifting market expectations and risk perceptions. Recent moves in container shipping...

Wondering if JinkoSolar Holding at around $25.64 is a bargain or a value trap? You are not alone. This stock often flies under the radar despite big swings in sentiment. Over the last week the share price is up 5.9%, but that bounce comes after a choppy stretch, with the stock down 6.1% over 30 days and still negative over 1 year and even more over 3 and 5 years. Recently, JinkoSolar has stayed in the spotlight with ongoing headlines about global clean energy policy shifts and intensifying...

The US Supreme Court’s earlier decision to review the government’s use of the International Economic Emergency Powers Act (IEEPA) for tariffs has introduced the risk that multiple 2025 bilateral tariff arrangements could be revisited, raising the prospect of renewed trade friction and supply chain disruption into 2026 for corporate clients worldwide. For Marsh & McLennan, a leading global risk and insurance adviser, this heightened policy and trade uncertainty sharpens the relevance of its...

If you are wondering whether Monolithic Power Systems is still worth buying after its massive run, or if the best days are already priced in, you are not alone. The stock is trading around $946.51, down a modest 1.7% over the last week and 1.2% over the last month, but still up an impressive 59.3% year to date and 56.9% over the past year, with multi year gains above 160%. Recent enthusiasm has been driven by Monolithic Power Systems' expanding role in power management solutions for data...

Astera Labs (ALAB) just doubled down on its AI data center ambitions by rolling out plans for custom connectivity solutions on top of its NVLink Fusion work with Nvidia and the aiXscale photonics acquisition. See our latest analysis for Astera Labs. That backdrop helps explain why the stock has been volatile lately: despite a sharp 1 day share price return of minus 14.31% and a 90 day share price return of minus 35.14%, the year to date share price return is still positive, and the 1 year...

Earlier this week, Compass, Inc., the largest U.S. residential real estate brokerage, reported a strong Q3 with revenue rising 23.6% year on year and EBITDA guidance ahead of expectations, prompting several major analysts to upgrade their views on the company amid optimism about synergies from its HOUS acquisition. Compass also released its first Housing Market Outlook, highlighting flattening prices, rising inventory, and improving wage-driven affordability, which together could encourage...

Q3 2025 Snapshot and Recent Trends Evommune (EVMN) just posted Q3 2025 results with revenue of about $10 million and a basic EPS loss of roughly $8.07, while trailing twelve month figures show total revenue of about $13 million and basic EPS of around minus $40.87. Over recent periods the company has seen revenue move from roughly $5 million on a trailing basis in Q4 2023 to about $7 million in Q4 2024, then to around $13 million by Q3 2025, even as quarterly basic EPS remained negative...